ABOUT PHARNEXT

Pharnext is an advanced clinical stage biopharmaceutical company developing new therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological diseases. The proprietary R&D platform of Pharnext is based on network pharmacology. It allows the development of synergistic combinations of repositioned drugs – pleodrugs – which benefit from an outstanding safety profile and IP with strong enforceability. The company’s two lead pleodrugs are PXT-3003 for the treatment of Charcot-Marie-Tooth disease type 1A (Phase 3 started) and PXT-864 for Alzheimer’s disease (Phase 2 ongoing) and other neurologic indications (Parkinson’s disease, amyotrophic lateral sclerosis).

PLEO-CMT STUDY

THE INTERNATIONAL PIVOTAL PHASE 3 STUDY OF PXT-3003 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1A IS ONGOING.
If you would like more information about this clinical trial, please visit the following websites:
For France: CMT France - http://www.cmt-france.org
For other European countries: OrphanDev - http://www.orphan-dev.org
For the US: Hereditary Neuropathy Foundation (HNF) - http://www.hnf-cure.org
Worldwide: ClinicalTrials - https://clinicaltrials.gov

Latest News

OrphanDev Collaboration for CMT Phase III Trial
Tuesday, 26 January 2016

OrphanDev Collaboration for CMT Phase III Trial

Press Release (EN or FR)
PXT-3003 in Phase III trial for CMT-1A
Tuesday, 15 December 2015

PXT-3003 in Phase III trial for CMT-1A

Press Release (EN or FR)
POSITIVE EFFECTS WITH PXT-864 IN PARKINSON’S DISEASE
Tuesday, 10 November 2015

POSITIVE EFFECTS WITH PXT-864 IN PARKINSON’S DISEASE

Press Release (EN or FR)
PXT-3003 FEATURED AT 2015 PNS BIENNIAL MEETING
Tuesday, 30 June 2015

PXT-3003 FEATURED AT 2015 PNS BIENNIAL MEETING

Press Release (EN or FR)